Sign in
CompletedPhase 4

Immunogenicity of Alternative Annual Influenza Vaccination Strategies in Older Adults in Hong Kong

Key facts

Who runs it
The University of Hong Kong
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 4
People taking part
1,861 people enrolled
Started
7 Oct 2017
Ended
31 Dec 2025
Type of study
Interventional, 11 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Standard inactivated influenza vaccine (NH formulation)
  • MF 59 adjuvanted inactivated influenza vaccine (NH formulation)
  • High-dose inactivated influenza vaccine (NH formulation)
  • Recombinant hemagglutinin inactivated influenza vaccine (NH formulation)
Record updated
15 May 2026

Who can take part

Age
65 years to 82 years
Sex
Women and men
Healthy volunteers
Can take part
Show the full registry criteria (5)Hide the full registry criteria

Who can take part

  • Adult aged 65-82 years attending ECC and EDC who has not received 2017/18 seasonal influenza vaccine and is willing to receive annual influenza vaccination

Who cannot take part

  • Individuals who report medical conditions not suitable to receive inactivated influenza vaccines, such as:; Severe allergic reaction (e.g., anaphylaxis) after previous dose of any influenza vaccine; or to a vaccine component, including egg protein; Moderate or severe acute illness with or without fever after any previous influenza vaccination; or; A history of Guillain-Barré syndrome (GBS) within 6 weeks of previous influenza vaccination
  • Individuals who show signs of dementia (do not pass the Mini-cog test under Appendix 1a: Recruitment Screening Log) or significant cognitive impairment and are not competent to give their consent
  • Individuals, who report medical conditions not suitable to receive intramuscular injection, such as:; bleeding disorders; habitually taking anticoagulants (with the exception of antiplatelets such as aspirin)
  • Individuals who have any medical conditions not suitable to receive inactivated influenza vaccines as determined by a clinician

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study allows to evaluate the strength and duration of immune responses between annual receipt of standard inactivated vaccine and alternative potent vaccines, including annual receipt of adjuvanted inactivated vaccine, annual receipt of high-dose inactivated vaccine, annual receipt of recombinant HA vaccine, and the alternate combinations of the former three vaccines over four years, for identifying improved vaccination strategies for influenza vaccination in older adults in a location experiencing a subtropical pattern in influenza activity.

The 11 groups in the trial

  • Standard vaccineExisting treatment, for comparison

    Once-annual administration of standard vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.

    Treatment: Standard inactivated influenza vaccine (NH formulation)

  • Alternating standard vaccine & adjuvanted vaccineTreatment being tested

    Alternating once-annual administration of standard inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.

    Treatment: Standard inactivated influenza vaccine (NH formulation) and MF 59 adjuvanted inactivated influenza vaccine (NH formulation)

  • Alternating adjuvanted vaccine & standard vaccineTreatment being tested

    Alternating once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of standard inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.

    Treatment: Standard inactivated influenza vaccine (NH formulation) and MF 59 adjuvanted inactivated influenza vaccine (NH formulation)

  • Alternating standard vaccine and high-dose vaccineTreatment being tested

    Alternating once-annual administration of standard inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of high-dose inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.

    Treatment: Standard inactivated influenza vaccine (NH formulation) and High-dose inactivated influenza vaccine (NH formulation)

  • Alternating high-dose vaccine and standard vaccineTreatment being tested

    Alternating once-annual administration of high-dose inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of standard inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.

    Treatment: Standard inactivated influenza vaccine (NH formulation) and High-dose inactivated influenza vaccine (NH formulation)

  • Alternating adjuvanted vaccine and high-dose vaccineTreatment being tested

    Alternating once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of high-dose inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.

    Treatment: MF 59 adjuvanted inactivated influenza vaccine (NH formulation) and High-dose inactivated influenza vaccine (NH formulation)

  • Alternating high-dose vaccine and adjuvanted vaccineTreatment being tested

    Alternating once-annual administration of high-dose inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.

    Treatment: MF 59 adjuvanted inactivated influenza vaccine (NH formulation) and High-dose inactivated influenza vaccine (NH formulation)

  • High-dose vaccineTreatment being tested

    Once-annual administration of high-dose inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.

    Treatment: High-dose inactivated influenza vaccine (NH formulation)

  • Adjuvanted vaccineTreatment being tested

    Once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.

    Treatment: MF 59 adjuvanted inactivated influenza vaccine (NH formulation)

  • Recombinant vaccineTreatment being tested

    Once-annual administration of recombinant hemagglutinin inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.

    Treatment: Recombinant hemagglutinin inactivated influenza vaccine (NH formulation)

  • Alternating recombinant vaccine and adjuvanted vaccineTreatment being tested

    Alternating once-annual administration of recombinant hemagglutinin inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.

    Treatment: MF 59 adjuvanted inactivated influenza vaccine (NH formulation) and Recombinant hemagglutinin inactivated influenza vaccine (NH formulation)

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Immunogenicity of Alternative Annual Influenza Vaccination Strategies in Older Adults in Hong Kong - a Randomized Controlled Trial
Publications
Record updated
15 May 2026